ADA 2026: Triple Hormone Therapies and Monthly Obesity Drugs Show Promise

References

1. 1.Blonde, L., Umpierrez, G., Reddy, S. S., McGill, J., Berga, S. L., Bush, M., ... & Handelsman, Y. (2024). American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice, 30(1), 8-54. https://doi.org/10.1016/j.eprac.2022.08.002
2. 2.Cooney, E. (2026). Triple hormone receptors, a monthly obesity drug, and a bittersweet ending. STAT News. https://www.statnews.com/2026/06/06/triple-g-safety-data-monthly-obesity-drug-ada-in-30/
3. 3.Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & STEP 2 Study Group. (2024). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. 4.Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., ... & Jastreboff, A. M. (2024). Efficacy and safety of LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist in patients with type 2 diabetes: a randomised, placebo-controlled, phase 2 trial. The Lancet, 403(10429), 768-780. https://doi.org/10.1016/S0140-6736(24)00367-2
5. 5.Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., ... & Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. (2024). American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice, 30(4), 280-315. https://doi.org/10.1016/j.eprac.2024.03.006
6. 6.Holst, J. J., & Rosenkilde, M. M. (2024). GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists. Nature Reviews Endocrinology, 20(5), 285-296. https://doi.org/10.1038/s41574-024-00969-1
7. 7.Khunti, K., Gomes, M. B., Pocock, S., Ekoe, J. M., Kalra, S., Baum, P., ... & DISCOVER Study Group. (2024). Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism, 26(7), 2654-2668. https://doi.org/10.1111/dom.15159
8. 8.Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., ... & Tschöp, M. H. (2024). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 80, 101928. https://doi.org/10.1016/j.molmet.2024.101928
9. 9.Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2024). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 79, 101870. https://doi.org/10.1016/j.molmet.2024.101870
10. 10.Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., ... & SURPASS-1 Investigators. (2024). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6
11. 11.Ryan, D. H., & Yockey, S. R. (2024). Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports, 13(2), 289-302. https://doi.org/10.1007/s13679-024-00521-4